APA-referens

Xu, C., Buczkowski, K. A., Zhang, Y., Asahina, H., Beauchamp, E. M., Terai, H., . . . Hammerman, P. S. (2015). NSCLC Driven by DDR2 Mutation is Sensitive to Dasatinib and JQ1 Combination Therapy. Mol Cancer Ther.

Chicago-stil citat

Xu, Chunxiao, et al. "NSCLC Driven By DDR2 Mutation Is Sensitive to Dasatinib and JQ1 Combination Therapy." Mol Cancer Ther 2015.

MLA-referens

Xu, Chunxiao, et al. "NSCLC Driven By DDR2 Mutation Is Sensitive to Dasatinib and JQ1 Combination Therapy." Mol Cancer Ther 2015.

Varning: dessa hänvisningar är inte alltid fullständigt riktiga.